Provided by Tiger Fintech (Singapore) Pte. Ltd.

Celldex Therapeutics

22.11
+0.90004.24%
Post-market: 22.280.1700+0.77%17:58 EDT
Volume:1.64M
Turnover:35.92M
Market Cap:1.47B
PE:-8.19
High:22.47
Open:21.10
Low:20.91
Close:21.21
Loading ...

Celldex Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Celldex Therapeutics Q1 EPS $(0.81) Misses $(0.74) Estimate, Sales $695.00K Miss $1.05M Estimate

Benzinga
·
09 May

Celldex Therapeutics Q1 Revenue USD 695 Thousand

THOMSON REUTERS
·
09 May

Celldex Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview

Reuters
·
06 May

Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
06 May

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

GlobeNewswire
·
06 May

Canada's Northern Graphite plans to put Quebec mine on care and maintenance

Reuters
·
01 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
01 May

Celldex Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
28 Apr

BUZZ-U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli Lilly

Reuters
·
20 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Five Below, QXO, PDD Holdings

Reuters
·
20 Mar

BUZZ-MS starts coverage on Celldex, bullish view on company's skin disease treatment

Reuters
·
20 Mar

Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target

MT Newswires Live
·
20 Mar

Celldex Therapeutics Initiated at Overweight by Morgan Stanley

Dow Jones
·
20 Mar

Celldex Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
04 Mar

Celldex Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
03 Mar

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

GlobeNewswire
·
03 Mar

Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

Celldex announces data from Phase 2 barzolvolimab studies

TIPRANKS
·
02 Mar

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

GlobeNewswire
·
02 Mar